Episode 334: 333. Cell Phone Use While Driving and Financial Gain

Episode 334: 333. Cell Phone Use While Driving and Financial Gain

Feedback and Financial Incentives for Reducing Cell Phone Use While Driving: A Randomized Clinical Trial | Public Health | JAMA Network Open | JAMA Network

Question Can behavioral interventions decrease handheld cell phone–based driver distraction?

17663 and ended up with 2020 participants

Progressive email--- already a select population

Outcome-- Proportion of drive time engaged in handheld phone use in seconds per hour (s/h) of driving.

Median baseline handheld phone use was 216 (IQR, 72-480) s/h.

Participants were randomly assigned to 1 of 6 trial arms for a 7-week intervention period: (1) control; (2) feedback, with weekly push notification about their handheld phone use compared with that of similar others; (3) standard incentive, with a maximum $50 award at the end of the intervention based on how their handheld phone use compared with similar others; (4) standard incentive plus feedback, combining interventions of arms 2 and 3; (5) reframed incentive plus feedback, with a maximum $7.15 award each week, framed as participant’s to lose; and (6) doubled reframed incentive plus feedback, a maximum $14.29 weekly loss-framed award.

standard incentive, with a maximum $50 award at the end of the intervention based on how their handheld phone use compared with similar others---- reduced their use by −38 (95% CI, −69 to −8) s/h (P = .045);

reframed incentive plus feedback, with a maximum $7.15 award each week, framed as participant’s to lose; and (-----reframed incentive plus feedback participants reduced their use by −56 (95% CI, −87 to −26) s/h (P < .001);

doubled reframed incentive plus feedback, a maximum $14.29 ($100) weekly loss-framed award.

and doubled reframed incentive plus feedback participants reduced their use by −42 s/h (95% CI, −72 to −13 s/h; P = .007).

remember

Median baseline handheld phone use was 216 (IQR, 72-480) s/h.

Their consclusions

Findings In this randomized clinical trial with 2020 participating auto insurance customers, the median baseline level of handheld phone while driving was 216 seconds per hour. Those randomized to interventions combining social comparison feedback and financial incentives reduced their handheld phone use while driving by 15% to 21% relative to the control group.

Episoder(388)

Episode 394: 402. Cardiovascular Risk Factors, Zilebesiran, Shared Decision Making

Episode 394: 402. Cardiovascular Risk Factors, Zilebesiran, Shared Decision Making

https://www.nejm.org/doi/10.1056/NEJMoa2415879?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Key Findings: Classic Risk Factors: The five risk factors examined were hype...

18 Jul 202515min

Episode 393: 404. 3 quick articles you might want to know about (oral semaglutide, tiktok, and GLP1 thyroid cancer)

Episode 393: 404. 3 quick articles you might want to know about (oral semaglutide, tiktok, and GLP1 thyroid cancer)

GLP1 might cause thyroid cancer in mice but the evidence is drastically lacking in humansOral semaglutide is expensive for an NNT of 50 at 4 yrsTiktok videos of skin care are a scam

25 Jun 202512min

Episode 392: 403. 3 Papers, 1 Podcast - One Guideline Changer

Episode 392: 403. 3 Papers, 1 Podcast - One Guideline Changer

https://jamanetwork.com/journals/jama/article-abstract/2834040amiloride is realistically equal to spironolactone for resistant HTNhttps://journals.lww.com/ajg/abstract/2025/05000/higher_rate_of_sponta...

16 Jun 202514min

Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

https://www.jthjournal.org/article/S1538-7836(25)00109-6/fulltextAntithrombotic agents, like aspirin and anticoagulants, are essential for treating many cardiovascular conditions. However, a common si...

5 Jun 20257min

Episode 390: 401. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

Episode 390: 401. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

https://jamanetwork.com/journals/jama/article-abstract/2834632SummaryThe article examines the effectiveness and safety of zilebesiran, an RNA interference therapeutic agent, when used in combination w...

4 Jun 20258min

Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

Episode 389: 400. CRP, Lipoprotein A, LDL for cardiac risk assessment

https://www.nejm.org/doi/full/10.1056/NEJMoa2405182?query=recirc_Semantic  Key Takeaways Extended Predictive Value of Biomarkers: High-sensitivity C-reactive protein (CRP), LDL cholesterol, and lipop...

29 Mai 20259min

Episode 388: 399. Use of albumin-adjusted calcium measurements in clinical practice

Episode 388: 399. Use of albumin-adjusted calcium measurements in clinical practice

Desgagnés N et al. Use of albumin-adjusted calcium measurements in clinical practice. JAMA Netw Open 2025 Jan 21; 8:e2455251. (https://doi.org/10.1001/jamanetworkopen.2024.55251)Overall, total calcium...

27 Mai 20257min

Episode 387: 398. Which is Better, Tirzepatide or Semaglutide?

Episode 387: 398. Which is Better, Tirzepatide or Semaglutide?

https://www.nejm.org/doi/10.1056/NEJMoa2416394At 72 weeks, the mean percentage decrease in weight was significantly greater with tirzepatide than with semaglutide (20% vs. 14%). Gastrointestinal side ...

21 Mai 20258min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
hvordan-har-du-det-mann
psykodrama
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
leger-om-livet
rss-garne-damer
foreldreradet
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
hormonelle-frida
hjernesterk
g-punktet
rss-lopedrommen
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
biohacking-girls-din-podcast-for-optimal-helse
helsetipspodden
treningsprat
sinnsyn